Sublingual films

• US 9,427,412 B2
• Filed: 02/03/2016
• Issued: 08/30/2016
• Est. Priority Date: 12/16/2010
• Status: Active Grant

• Current Assignee: Sunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
• Original Assignee: Cynapsus Therapeutics Inc. (Sumitomo Pharma America, Inc.)
• Inventors: Bryson, Nathan John, Giovinazzo, Anthony John, Barnhart, Scott David, Koons, Michael Clinton
• Primary Examiner(s): Park, H. Sarah
• Application Number:
  US15/014,655
• Publication Number:
  US 20160151299A1
• Time in Patent Office: 209 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61F 13/00063 comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic drug delivery dressings A61K9/70; chemical aspect of the additives A61L15/00
• CPC Class Codes: A61J 1/03 for pills or tablets containers for pills or tablets with special dispensing means therefor B65D83/04
• CPC Class Codes: A61J 7/0053 Syringes, pipettes or oral dispensers
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 31/428 condensed with carbocyclic rings
• CPC Class Codes: A61K 31/4415 Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/48 Ergoline derivatives, e.g. lysergic acid, ergotamine
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 : Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/006 : Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/209 : containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/7007 : Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B29C 39/18 : incorporating preformed parts or layers, e.g. casting around inserts or for coating articles B29C39/206 takes precedence
• CPC Class Codes: B29C 39/38 : Heating or cooling
• CPC Class Codes: B29C 43/305 : Making multilayered articles
• CPC Class Codes: B29C 43/52 : Heating or cooling
• CPC Class Codes: B29C 65/70 : by moulding using a particular moulding technique, see the relevant technique , e.g. by injection B29C45/14467
• CPC Class Codes: B29C 66/45 : Joining of substantially the whole surface of the articles methods or apparatus for laminating B32B37/00
• CPC Class Codes: B29K 2001/00 : Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
• CPC Class Codes: B29L 2007/008 : Wide strips, e.g. films, webs
• CPC Class Codes: B29L 2009/00 : Layered products
• CPC Class Codes: B29L 2031/753 : Medical equipment; Accessories therefor bloodbags, medical bags B29L2031/7148; artificial eyes B29L2011/0008
• CPC Class Codes: B29L 2031/755 : Membranes, diaphragms
• CPC Class Codes: B65D 65/38 : Packaging materials of special type or form

Abstract

The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson'"'"'s disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Claims

1. A pharmaceutical composition in unit dosage form formulated for sublingual administration, wherein said unit dosage form is a film comprising (i) from 25±

5% to 40±

5% (w/w) an acid addition salt of apomorphine and (ii) from 6±

2% to 65±

5% (w/w) a pH neutralizing agent that is an inorganic base selected from sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, and potassium phosphate tribasic, wherein said film comprises particles comprising an acid addition salt of apomorphine and particles comprising said inorganic base.

2. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises from 6±

2% to 25±

5% (w/w) of said pH neutralizing agent.

3. The pharmaceutical composition of claim 2, wherein said unit dosage form comprises from 6±

2% to 10±

2% (w/w) of said pH neutralizing agent.

4. The pharmaceutical composition of claim 1, wherein said pH neutralizing agent is potassium phosphate dibasic.

5. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises from 2 to 60 mg of said acid addition salt of apomorphine.

6. The pharmaceutical composition of claim 1, wherein said unit dosage form further comprises from 3 to 12% (w/w) plasticizing agent.

7. The pharmaceutical composition of claim 6, wherein said plasticizing agent is a polyol, oleic acid, or triacetin.

8. The pharmaceutical composition of claim 7, wherein said plasticizing agent is a polyol selected from sorbitol, mannitol, maltitol, xylitol, glycerol, propylene glycol, and polyethylene glycol.

9. The pharmaceutical composition of claim 1, wherein said unit dosage form further comprises from 1 to 50% (w/w) hydrolyzed starch.

10. The pharmaceutical composition of claim 9, wherein said hydrolyzed starch is a dextrin or a maltodextrin.

11. The pharmaceutical composition of claim 1, wherein said unit dosage form further comprises an antioxidant.

12. The pharmaceutical composition of claim 1, wherein said unit dosage form further comprises from 0.05 to 2.5% (w/w) metabisulfite.

13. The pharmaceutical composition of claim 1, wherein said unit dosage form further comprises from 0.2 to 5% (w/w) of a permeation enhancer.

14. The pharmaceutical composition of claim 1, wherein said unit dosage form further comprises from 0.2 to 5% (w/w) of glycerol monostearate.

15. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, or methyl cellulose.

16. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 4±

1 mg of apomorphine hydrochloride.

17. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 8±

2 mg of apomorphine hydrochloride.

18. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 10±

3 mg of apomorphine hydrochloride.

19. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 12±

3 mg of apomorphine hydrochloride.

20. The pharmaceutical composition of claim 1, wherein the pyridoxine is present in an amount such that a unit dosage form placed in 1 mL of unbuffered water at pH 7 results in a pH of between 2.5 and 8.0.

21. The pharmaceutical composition of claim 1, wherein said acid addition salt of apomorphine is apomorphine hydrochloride.

22. The pharmaceutical composition of claim 1, wherein said unit dosage form is a monolayer film.

23. A method of treating Parkinson'"'"'s disease in a subject, said method comprising sublingual administration of the pharmaceutical composition of claim 1 in an amount effective to treat said subject.